Neurocrine defines a 6‑point EQ‑VAS threshold and reports a 13.1‑point health gain in tardive dyskinesia patients
Neurocrine Biosciences analyzed patient‑reported outcomes from its Phase 4 KINECT‑PRO study and established a 6‑point rise on the EQ‑VAS as the minimum clinically meaningful improvement for tardive dyskinesia patients treated with INGREZZA. The same study showed an average 13.1‑point increase in overall health scores after 24 weeks of therapy. The research will be shared at the Academy of Managed Care Pharmacy Nexus 2026 conference.
Why it matters
The new benchmark gives clinicians a concrete reference for interpreting health‑related quality‑of‑life gains with INGREZZA, which may influence prescribing decisions and market perception of the drug. No immediate financial impact is disclosed, but the data could affect investor sentiment toward NBIX.
Key facts
- 1Neurocrine identified a 6‑point increase on the EQ‑VAS as the threshold for a clinically meaningful health improvement in tardive dyskinesia patients treated with INGREZZA. stocktitan.net
- 2The Phase 4 KINECT‑PRO study reported a mean 13.1‑point improvement in EQ‑VAS scores after 24 weeks of treatment. rttnews.com
- 3KINECT‑PRO is an open‑label, 24‑week Phase 4 trial evaluating INGREZZA in tardive dyskinesia patients. stocktitan.net
- 4Neurocrine will present the analysis at the Academy of Managed Care Pharmacy Nexus 2026 conference. rttnews.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.